ATHE
Alterity Therapeutics LimitedNASDAQHealthcare$3.60+1.34%ClosedMarket Cap: $32.7M
As of 2026-04-07
Valuation
P/E (TTM)
—
PEG
—
P/B
1.69
P/S
25.54
EV/EBITDA
-2.43
DCF Value
$-14.68
FCF Yield
-2.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
96.8%
Operating Margin
-525.6%
Net Margin
-380.7%
ROE
-30.2%
ROA
-25.6%
ROIC
-31.3%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q2 2026 | $0.00 | -Infinity% | $-12.8M | $-9.4M | $-0.54 | — |
| Q4 2025 | $3.8M | 98.3% | $-7.1M | $-5.0M | $-0.42 | — |
| FY 2025 | $5.4M | 97.7% | $-14.6M | $-12.1M | $-1.14 | — |
| Q2 2025 | $1.6M | 96.0% | $-7.5M | $-7.2M | $-0.84 | — |
| Q4 2024 | $2.1M | 96.5% | $-13.0M | $-12.6M | $-1.20 | — |
| FY 2024 | $4.0M | 94.7% | $-19.6M | $-19.1M | $-3.12 | — |
| Q2 2024 | $1.9M | 96.1% | $-4.5M | $-6.5M | $-1.56 | — |
| Q4 2023 | $1.5M | 96.6% | $-7.8M | $-5.8M | $-1.44 | — |
| FY 2023 | $3.9M | 92.7% | $-14.6M | $-13.8M | $-3.42 | — |
| Q2 2023 | $2.4M | 97.9% | $-10.7M | $-8.0M | $-1.98 | — |
| Q4 2022 | $2.8M | 99.2% | $-10.5M | $-6.3M | $-1.56 | — |
| FY 2022 | $5.1M | 92.9% | $-15.5M | $-12.8M | $-3.18 | — |